- Male and female patients ≥ 18 years
- Declaration of informed consent signed by patient
- Patients with a solid tumour or with a malignant haematological tumour
- Patients who have been prescribed cytotoxic chemotherapy, irrespective of current
cycle
- GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last
three months before enrolment
- Patients starting primary prophylactic treatment using NivestimTM either to shorten
the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN
- Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS)
- Patients who are hypersensitive to one of the excipients of NivestimTM
- Patients not undergoing chemotherapy
- Patients being treated curatively or as secondary prophylaxis with G-CSF